62842 Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 

where the following criteria were 

applied: Objectives and Need for 

Assistance, Facilities and Resources, 

Cost, and Relevance to ACF. 

The Federal objective reviewers 

determined that the proposal evidenced 

a high technical quality, with wellqualified staff from respected 

institutions operating within a 

reasonable budget. Reviewers found that 

the proposal would add value compared 

to past research, through its focus on 

long-term child-only caseload 

dynamics, its use of State data, and its 

analysis of types of case that have not 

received as much attention in past 

research. The panel also pointed out 

that child-only cases are a high priority 

issue for ACF. The proposed project 

offers an updated and more detailed 

picture of the TANF child-only 

caseload, including the dynamics of 

client entry and exit from the caseload. 

It also provides a timely opportunity, in 

light of pending TANF reauthorization, 

to gather policy information about a 

vulnerable and important ACF client 

group. 

OPRE will administer the grant in 

collaboration with HHS—Office of the 

Assistant Secretary for Planning and 

Evaluation (ASPE). 

FOR FURTHER INFORMATION CONTACT: 

Matthew Borus, Office of Planning, 

Research and Evaluation, 

Administration for Children and 

Families, 370 L’Enfant Promenade, SW., 

Washington, DC 20447; Telephone: 

202–401–5739; E-mail: 

Matthew.Borus@acf.hhs.gov. 

Dated: October 6, 2010. 

Naomi Goldstein, 

Director, Office of Planning, Research and 

Evaluation. 

[FR Doc. 2010–25722 Filed 10–12–10; 8:45 am] 

BILLING CODE 4184–07–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories Which 

Meet Minimum Standards To Engage in 

Urine Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and April 30, 2010 

(75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://www.workplace.

samhsa.gov and http://www.drugfree

workplace.gov. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 

2–1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) must meet in order to conduct 

drug and specimen validity tests on 

urine specimens for Federal agencies. 

To become certified, an applicant 

Laboratory/IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a Laboratory/IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification do not 

meet the minimum requirements 

described in the HHS Mandatory 

Guidelines. A Laboratory/IITF must 

have its letter of certification from HHS/ 

SAMHSA (formerly: HHS/NIDA) which 

attests that it has met minimum 

standards. 

In accordance with the Mandatory 

Guidelines dated April 30, 2010 (75 FR 

22809), the following Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) meet the minimum standards to 

conduct drug and specimen validity 

tests on urine specimens: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328– 

7840/800–877–7016, (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 Hill 

Ave., Nashville, TN 37210, 615–255– 

2400, (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.) 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823, (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130, (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783, 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671– 

2281, 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

DynaLIFE Dx*, 10150–102 St., Suite 

200, Edmonton, Alberta, Canada T5J 

5E2, 780–451–3702/800–661–9876, 

(Formerly: Dynacare Kasper Medical 

Laboratories). 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

mstockstill on DSKH9S0YB1PROD with NOTICES

Federal Register / Vol. 75, No. 197 / Wednesday, October 13, 2010 / Notices 62843 

08869, 908–526–2400/800–437–4986, 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984, 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339, (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845, 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.,). 

Maxxam Analytics*, 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8, 905–817–5700, (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, 

Forensic Toxicology Laboratory, 1 

Veterans Drive, Minneapolis, MN 

55417, 612–725–2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304, 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504, 888–747–3774, (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942, (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121, 858–643– 

5555. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432, (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216, 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304, 

800–877–2520, (Formerly: SmithKline 

Beecham Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109, 

505–727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601, 574–234–4176 x1276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040, 602–438–8507/800–279– 

0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101, 405–272– 

7052. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 

305–593–2260. 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. 

* The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 30, 2010 (75 FR 

22809). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Dated: October 6, 2010. 

Elaine Parry, 

Director, Office of Management, Technology, 

and Operations, SAMHSA. 

[FR Doc. 2010–25705 Filed 10–12–10; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Advisory Council on Blood Stem Cell 

Transplantation; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), notice is hereby given 

of the following meeting: 

Name: Advisory Council on Blood Stem 

Cell Transplantation. 

Date and Times: November 15, 2010, 8:30 

a.m. to 4:30 p.m. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, Maryland 

20814. 

Status: The meeting will be open to the 

public. 

Purpose: Pursuant to Public Law 109–129, 

42 U.S.C. 274k (section 379 of the Public 

Health Service Act, as amended) the 

Advisory Council on Blood Stem Cell 

Transplantation (ACBSCT) advises the 

Secretary of HHS and the Administrator, 

HRSA, on matters related to the activities of 

the C.W. Bill Young Cell Transplantation 

Program (Program) and the National Cord 

Blood Inventory (NCBI) Program. 

Agenda: The Council will hear reports 

from five ACBSCT Work Groups: Cord Blood 

Bank Collections, Realizing the Potential of 

Cord Blood, Scientific Factors Necessary to 

Define a Cord Blood Unit as High Quality, 

Cord Blood Thawing and Washing, and 

Access to Transplantation. The Council also 

will hear presentations and discussions on 

the following topics: Arizona reimbursement 

concerns for Medicaid beneficiaries, 

Myelodysplastic Syndromes (MDS) coverage, 

Medicare reimbursement for costs for 

allogeneic or autologous transplants, 

legislative reauthorization and 

appropriations bills, and Program 

performance measures. Agenda items are 

subject to change as priorities indicate. 

After the presentations and Council 

discussions, members of the public will have 

an opportunity to provide comments. 

Because of the Council’s full agenda and the 

timeframe in which to cover the agenda 

topics, public comment will be limited. All 

public comments will be included in the 

mstockstill on DSKH9S0YB1PROD with NOTICES